Cargando…

Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) Trial

BACKGROUND: In the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) trial, apixaban was noninferior to enoxaparin/warfarin in preventing recurrent symptomatic venous thromboembolism (VTE) or venous thromboembolism–related death, with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xianchen, Johnson, Margot, Mardekian, Jack, Phatak, Hemant, Thompson, John, Cohen, Alexander T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845271/ https://www.ncbi.nlm.nih.gov/pubmed/26627879 http://dx.doi.org/10.1161/JAHA.115.002340

Ejemplares similares

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018)

Idiopathic pulmonary vein thrombosis treated with apixaban
por: Ngo, Dallis, et al.
Publicado: (2021)

Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018)

Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date
por: Trkulja, Vladimir
Publicado: (2016)

Apixaban/tocilizumab interaction: Venous thromboembolism: case report
Publicado: (2021)

Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY
por: Cohen, Alexander T., et al.
Publicado: (2021)

Development of New Deep Venous Thrombosis While on Apixaban
por: Sharma, Munish, et al.
Publicado: (2017)

Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review
por: Mandernach, Molly W, et al.
Publicado: (2015)

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
por: Hendriks, Stephan V., et al.
Publicado: (2020)

Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia
por: Sattler, Laurent, et al.
Publicado: (2023)

Correction to: Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY
por: Cohen, Alexander T., et al.
Publicado: (2021)

Long-term Anticoagulation with Apixaban in Patients with Cerebral Venous Thrombosis
por: Bharath, Suman Preet, et al.
Publicado: (2023)

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
por: Lip, Gregory Y. H., et al.
Publicado: (2018)

Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
por: Werth, Sebastian, et al.
Publicado: (2012)

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence
por: Zalpour, Ali, et al.
Publicado: (2014)

Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis
por: Cohen, Alexander, et al.
Publicado: (2021)

Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2015)

Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States
por: Lip, Gregory Y. H., et al.
Publicado: (2016)

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
por: Tepper, Ping G., et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
por: Cohen, Alexander T., et al.
Publicado: (2021)

Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States
por: Deitelzweig, Steven, et al.
Publicado: (2018)

Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands: Clinical and Economic Effects
por: de Jong, Lisa A., et al.
Publicado: (2018)

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
por: Reda, Sara, et al.
Publicado: (2022)

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
por: Cohen, Alexander T., et al.
Publicado: (2023)

Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database
por: Guo, Jennifer D., et al.
Publicado: (2020)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
por: Cornell, Robert Frank, et al.
Publicado: (2019)

Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability
por: Lee, Juseung, et al.
Publicado: (2023)

Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
por: Sindet-Pedersen, Caroline, et al.
Publicado: (2017)

Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure–Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism
por: Byon, W, et al.
Publicado: (2017)

Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry
por: Beyer-Westendorf, Jan, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status
por: Cohen, Alexander T., et al.
Publicado: (2021)

Apixaban for the treatment of saphenous vein graft thrombosis presenting as unstable angina: a case report
por: Saigan, Makoto, et al.
Publicado: (2017)

Renal Vein Thrombosis Treated With Apixaban in a Patient With COVID-19: A Case Report
por: Kakhktsyan, Tigran, et al.
Publicado: (2023)

Medication non‐adherence as a cause of apixaban failure in venous thromboembolism: The importance of pharmacist medication reconciliation
por: Jethwa, Trisha E, et al.
Publicado: (2022)

CLRM-03 INCIDENCE OF INTRACRANIAL HEMORRHAGE IN GLIOMA PATIENTS WITH VENOUS THROMBOEMBOLISM CONVERTED FROM LMWH TO APIXABAN
por: Aboud, Orwa, et al.
Publicado: (2022)

D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study
por: Palareti, Gualtiero, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nnh5hju3htn5nqesd72ig2rh2u